Fate Therapeutics Inc (FATE)

[jondoeuk]

The posters

Long-term Stability Assessment of Cryopreserved iPSC-derived T and NK Cells Supports Mass Production and Off-the-shelf Therapeutic Applications https://fatetherapeutics.com/wp-content/uploads/2022/05/1-2022-ASGCT-iNK-and-iT-DP-stability-Draft-2-VFINAL.pdf

Long-term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-shelf Immunotherapies https://fatetherapeutics.com/wp-content/uploads/2022/05/2-2022-ASGCT-iCD34-to-iNK-and-iT-stability_vFINAL.pdf

Development of Next-Generation, Off-the-Shelf CAR T-cell Immunotherapies for Solid Tumors https://fatetherapeutics.com/wp-content/uploads/2022/05/3-ASGCT2022_Multiplexed-CAR-iT_Pan_VFINAL.pdf

Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy https://fatetherapeutics.com/wp-content/uploads/2022/05/4-2022_ASGCT_Stealth_MJ_VFINAL_09May2022.pdf

10-year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization https://fatetherapeutics.com/wp-content/uploads/2022/05/5-ASGCT-2022-iPSC-Stability-Poster-NDB-Final_.pdf

Robust T-cell Cellular Reprogramming and Single-cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T cells https://fatetherapeutics.com/wp-content/uploads/2022/05/6-AGGCT-2022_Robust-T-cell-Cellular-Reprogramming-and-Single-cell-Engineering-Platform_VFinal.pdf

iPSC-derived CD38-null NK cells in Combination with CD38-targeted Antibody Represent a Novel Therapeutic Strategy to Reduce the Requirement of Conditioning Chemotherapy for Off-the-Shelf Cell-based Cancer Immunotherapy https://fatetherapeutics.com/wp-content/uploads/2022/05/7-2022_ASGCT_CD38-conditioning_Final.pdf

FT536: A First-of-Kind, Off-the-Shelf CAR-iNK Cell Product Candidate for Solid Tumors Designed to Specifically Target MICA/B Stress Proteins and Overcome Mechanisms of Tumor Evasion https://fatetherapeutics.com/wp-content/uploads/2022/05/2-2022_ASGCT_FT536_vFinal.pdf